Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.
| Revenue (Most Recent Fiscal Year) | $564.17M |
| Net Income (Most Recent Fiscal Year) | $37.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.48 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.66 |
| Pre-Tax Margin (Trailing 12 Months) | -7.60% |
| Net Margin (Trailing 12 Months) | -19.94% |
| Return on Equity (Trailing 12 Months) | -23.89% |
| Return on Assets (Trailing 12 Months) | -11.13% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.00 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.07 |
| Inventory Turnover (Trailing 12 Months) | 4.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 128.68M |
| Free Float | 104.48M |
| Market Capitalization | $221.32M |
| Average Volume (Last 20 Days) | 0.90M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 49.57% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |